Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma 

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.

  • Disclosure of Conflicts of Interest

    Dr. Matthew Davids discloses the following:
    Consulting: AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, MEI Pharma, Merck, Mingsight, Nuvalent, Secura Bio, Takeda, and TG Therapeutics
    Research Support: AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Surface Oncology, and TG Therapeutics
    Royalties: UpToDate, Inc 

  • Target Audience

    This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with CLL and MCL.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Critically analyze recent clinical data regarding the efficacy and effectiveness of ncBTKi for the treatment of R/R CLL and R/R MCL.
    2. Formulate effective treatment regimens involving ncBTKi for the treatment of R/R CLL and R/R MCL.
    3. Compare and contrast the toxicities associated with covalent BTKi, ncBTKi, and other therapies for R/R CLL and R/R MCL.
    4. Discuss how safety considerations might affect treatment selection for individual patients with R/R CLL or R/R MCL in the community practice setting.
    5. Place ncBTKi in the context of other effective therapies for R/R CLL and R/R MCL.
    6. Propose approaches to optimize therapy for patients with R/R CLL and R/R MCL in the community setting, considering current knowledge about ncBTKi and other available therapies.
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and PleXus Communications. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Credit
    Medical Education Resources designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Credit
    Medical Education Resources designates this live activity for a maximum of 1.0 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

    Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.

    Pharmacy Credit


    Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
    Universal Program Number – JA0003680-0000-24-075-L01-P

    This activity is certified as Knowledge based CPE. 

  • Disclaimer

    Disclosure of Relevant Financial Relationships
    Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company. 

    Accredited Provider Disclosures
    The provider of this activity has nothing to disclose.

    Planners’ and Managers’ Disclosures
    The remaining planners and managers of this activity have nothing to disclose.

    Disclosure of Unlabeled Use
    In accordance with requirements of the FDA, the audience is advised that information presented in some continuing education activities may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

    Disclaimer
    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, PleXus Communications and Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management. 

  • Provider(s)/Educational Partner(s)

     

    Jointly provided by Medical Education Resources and Plexus Communications. This activity is held in partnership with the CLL Society.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.

  • Disclosure of Conflicts of Interest

    Dr. Matthew Davids discloses the following:
    Consulting: AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, MEI Pharma, Merck, Mingsight, Nuvalent, Secura Bio, Takeda, and TG Therapeutics
    Research Support: AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Surface Oncology, and TG Therapeutics
    Royalties: UpToDate, Inc 

  • Target Audience

    This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with CLL and MCL.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Critically analyze recent clinical data regarding the efficacy and effectiveness of ncBTKi for the treatment of R/R CLL and R/R MCL.
    2. Formulate effective treatment regimens involving ncBTKi for the treatment of R/R CLL and R/R MCL.
    3. Compare and contrast the toxicities associated with covalent BTKi, ncBTKi, and other therapies for R/R CLL and R/R MCL.
    4. Discuss how safety considerations might affect treatment selection for individual patients with R/R CLL or R/R MCL in the community practice setting.
    5. Place ncBTKi in the context of other effective therapies for R/R CLL and R/R MCL.
    6. Propose approaches to optimize therapy for patients with R/R CLL and R/R MCL in the community setting, considering current knowledge about ncBTKi and other available therapies.
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and PleXus Communications. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Credit
    Medical Education Resources designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Credit
    Medical Education Resources designates this live activity for a maximum of 1.0 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

    Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hours.

    Pharmacy Credit


    Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
    Universal Program Number – JA0003680-0000-24-075-L01-P

    This activity is certified as Knowledge based CPE. 

  • Disclaimer

    Disclosure of Relevant Financial Relationships
    Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company. 

    Accredited Provider Disclosures
    The provider of this activity has nothing to disclose.

    Planners’ and Managers’ Disclosures
    The remaining planners and managers of this activity have nothing to disclose.

    Disclosure of Unlabeled Use
    In accordance with requirements of the FDA, the audience is advised that information presented in some continuing education activities may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

    Disclaimer
    The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, PleXus Communications and Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management. 

  • Provider(s)/Educational Partner(s)

     

    Jointly provided by Medical Education Resources and Plexus Communications. This activity is held in partnership with the CLL Society.

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule14 Oct 2024